Chapter 8. Coronary Heart Disease
1. Centers For Disease Control And Prevention (CDC). National Center For Health Statistics. Health, United States. 2006.
2. Saydah SH, Eberhardt MS. Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. Journal of Alternative & Complementary Medicine 12(8):805-12, 2006.
3. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. American Journal of Cardiology 98(5):673-80, 2006.
4. Chagan L. Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York city. Bernstein DA, Cheng JW, Kirschenbaum HL, Rosenfeld V, Caliendo GC, Meyer J et al., editors. BMC Complementary & Alternative Medicine 5[4]. 2005.
5. Krasuski RA, Michaelis K, Eckart RE. The cardiovascular patient’s perceptions of complementary and alternative medicine. Clinical Cardiology 29(4):161-4, 2006.
6. Diaz M. Antioxidants and atherosclerotic heart disease. Frei B, Vita JA, Keaney JF Jr, editors. N Engl J Med 337[6], 408-416. 1997.
7. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men.[see comment]. New England Journal of Medicine 328(20):1450-6, 1993.
8. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women.[see comment]. New England Journal of Medicine 328(20):1444-9, 1993.
9. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004):781-6.
10. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.[see comment]. Lancet 356(9237):1213-8, 2000.
11. Anonymous. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999; 354(9177):447-55.
12. Hodis HN, Mack WJ, LaBree L et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106(12):1453-9, 2002.
13. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3):154-60.
14. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.[see comment]. JAMA 293(11):1338-47, 2005.
15. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.[see comment][erratum appears in Lancet. 2004 Feb 21;363(9409):662]. Lancet 361(9374):2017-23, 2003.
16. Miller ER III. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E, editors. Ann Intern Med 142[1], 37-46. 2005.
17. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.[see comment]. JAMA 288(19):2432-40, 2002.
18. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.[see comment]. Arteriosclerosis, Thrombosis & Vascular Biology 21(8):1320-6, 2001.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.[see comment][summary for patients in J Fam Pract. 2002 Oct;51(10):810; PMID: 12401142]. Lancet 360(9326):23-33, 2002.
20. Bjelakovic G. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Nikolova D, Gluud LL, Simonetti RG, Gluud C, editors. Jama 297[8], 842-857. 2007.
21. Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Albanes D, Huttunen JK. Postintervention effect of alpha tocopherol and beta carotene on different strokes: a 6-year follow-up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. Stroke 35(8):1908-13, 2004.
22. Tornwall ME, Virtamo J, Korhonen PA et al. Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. European Heart Journal 25(13):1171-8, 2004.
23. The Alpha-Tocopherol BCCPSG. The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers. N Engl J Med 330, 1029-1035. 1994.
24. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. [Review] [92 refs]. Biofactors 9(2-4):273-84, 1999.
25. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Archives of Neurology 61(6):889-92, 2004.
26. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase Inhibitors. Mol Aspects Med 1997; 18:137S-144S.
27. Mabuchi H, nohara A, Kobayashi J et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 195[2], e182-e189. 2007.
28. Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990; 87(22):8931-8934.
29. Young J, Florkowski C, Molyneux S et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. American Journal of Cardiology 100[9], 1400-1403. 2007.
30. Folkers K. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Vadhanavikit S, Mortensen A, editors. Proc Natl Acad Sci 82, 901-904. 1985.
31. Folkers K. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Langsjoen P, Langsjoen P, editors. Biochemical and Biophysical Research Communications 182, 247-253. 1992.
32. Rosenfeldt F. Coenzyme Q10 improves the tolerance of the senescent myocardium to aerobic and ischemic stress: studies in rats and in human artrial tissue. Pepe S, Ou R, Mariani J, Rowland M, Nagley P, Linnane A, editors. Biofactors 9, 291-299. 1999.
33. Rosenfeldt F. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. Marasco S, Lyon W, Wowk M, Sheeran F, Bailey M, Esmore D et al., editors. J Thorac Cardiovasc Surg 129[1], 25-32. 2005.
34. Singh RB, Wander GS, Rastogi A et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovascular Drugs & Therapy 1998; 12(4):347-353.
35. Singh RB, Neki NS, Kartikey K et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Molecular & Cellular Biochemistry 246(1-2):75-82, 2003.
36. Singh RB, Niaz M. Serum concentration of lipoprotein (a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. Int J Cardiol 1998; 68:23-29.
37. Gundling K, Ernest E. Complementary and alternative medicine in cardiovascular disease: what is the evidence it works? West J Med 1999; 171(3):191-194.
38. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 344, 1372-1373. 2007.
39. Engelsen J. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Nielsen J, Winther K, editors. Thromb Haemost 87[6], 1075-1076. 2002.
40. Eikelboom JW, Lonn E, Genest J, Jr., Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence [see comments]. [Review] [95 refs]. Ann Intern Med 1999; 131(5):363-375.
41. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325(7374):1202, 2002.
42. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Jama 288, 2015-2022. 2002.
43. Toole J. Lowering Homocysteine in Patients with Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death. Malinow MR, Chambless LE, Spence JD, Pettigrew JD, Howard V, Sides E et al., editors. Jama 291, 565-575. 2004.
44. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. N Engl J Med 354, 1567-1577. 2006.
45. Liem A, Reynierse-Buitenwerf G, Zwinderman A, Jukema J, van Veldhuisen D. Secondary prevention with folic acid: results of the Goes extension study. Heart 91, 1213-1214. 2005.
46. Bonaa KH, Njolstad I, Ueland PM et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction.[see comment]. New England Journal of Medicine 354(15):1578-88, 2006.
47. Lange H, Suryapranata H, De Luca G et al. Folate Therapy and In-Stent Restenosis after Coronary Stenting. N Engl J Med 350, 2673-2681. 2004.
48. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345, 1593-1600. 2001.
49. Moens A, Claeys M, Wuyts F et al. Effect of folic acid on endothelial function following actue myocardial infarction. American Journal of Cardiology 99[4], 476-481. 2007.
50. Doshi SN, McDowell IF, Moat SJ et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largerly independent of homocysteine lowering. Circulation 105, 22-26. 2002.
51. Gebauer SK, Psota TL, Harris WS, Kris-Etherton PM. n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. [Review] [88 refs]. American Journal of Clinical Nutrition 83(6 Suppl):1526S-1535S, 2006.
52. Woodside J, Kromhout D. Fatty acids and CHD. Proceedings of the Nutrition Society 64, 554-564. 2005.
53. Burr M, Fehily A, Gilbert J. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial. Lancet 1989; 2:757-761.
54. Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098. 2007.
55. Nilsen DAG, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. American Journal of Clinical Nutrition 74, 50-56. 2001.
56. Bucher H, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. American Journal of Medicine 112, 298-304. 2002.
57. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association.Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.[erratum appears in Circulation. 2003 Jan 28;107(3):512.]. Circulation 106(21):2747-57, 2002.
58. Eritsland J, Arnesen H, Seljeflot I, Kierulf P. Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagulation & Fibrinolysis 6, 17-22. 1995.
59. Bender N, Kraynak M, Chiquette E, Linn W, Clark G, Bussey H. Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy. Journal of Thrombosis and Thrombolysis 5, 257-261. 1998.
60. McClaskey EM, Michalets EL. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy 27(1):152-60, 2007.
61. Kinsella JE, Lokesh B, Stone RA. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms.[see comment]. [Review] [418 refs]. American Journal of Clinical Nutrition 52(1):1-28, 1990.
62. Hu FB, Stampfer MJ, Manson JE et al. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women.[see comment]. American Journal of Clinical Nutrition 69(5):890-7, 1999.
63. Daviglus ML, Stamler J, Orencia AJ et al. Fish consumption and the 30-year risk of fatal myocardial infarction.[see comment]. New England Journal of Medicine 336(15):1046-53, 1997.
64. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. Cardiovascular Drugs & Therapy 1997; 11(3):485-491.
65. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation 2002; 106(21):2747-2757.
66. Brouwer I, Katan MB, Zock PL. Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. Journal of Nutrition 134, 919-922. 2004.
67. Rahman K. Historical perspective on garlic and cardiovascular disease. [Review] [29 refs]. Journal of Nutrition 131(3s):977S-9S, 2001.
68. Williams M, Sutherland W, McCormick M, Yeoman D, de Jong S. Aged Garlic Extract Improves Endothelial Function in Men with Coronary Artery Disease. Phytotherapy Research 19, 314-319. 2005.
69. Lau BH. Suppression of LDL oxidation by garlic. Journal of Nutrition 131, 985S-988S. 2001.
70. Munday JS, James KA, Fray LM, Kirkwood SW, Thompson KG. Daily supplementation with aged garlic extract, but not raw garlic, protects low density lipoprotein against in vitro oxidation. Atherosclerosis 1999; 143(2):399-404.
71. Dillon S, Lowe G, Billington D, Rahman K. Dietary supplementation with aged garlic extract reduces plasma and urine concentrations of 8-iso-prostaglandin F-2 alpha in smoking and nonsmoking men and women. Journal of Nutrition 132, 168-171. 2002.
72. Morihara N, Sumioka I, Moriguchi T, Uda N, Kyo E. Aged garlic extract enhances production of nitric oxide. Life Sciences 71(5):509-17, 2002.
73. Kim-Park S, Ku D. Garlic elicits a nitric oxide-dependent relaxation and inhibits hypoxic pulmonary vasoconstriction in rats. Clin Exp Pharmacol Physiol 27, 780-786. 2000.
74. Mulrow CD, Lawrence V, Ackermann R et al. Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report: Technology Assessment (Summary) 20, 1-4. 2000.
75. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. [Review] [65 refs]. Ann Intern Med 2000; 133(6):420-429.
76. Superko HR, Krauss RM. Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a). J Am Coll Cardiol 2000; 35(2):321-6.
77. Gardner CD, Chatterjee LM, Carlson JJ. The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. Atherosclerosis. 2001;154:213-20.
78. Banerjee S, Maulik SK. Effect of garlic on cardiovascular disorders: a review. Nutrition Journal 19, 1-4. 2002.
79. Ackermann R, Mulrow CD, Ramirez G, Garnder C, Morbidoni L, Lawrence V. Garlic shows promise for improving some cardiovascular risk factors. Archives of Internal Medicine 161, 813-824. 2001.
80. Koscielny J, Klussendorf D, Latza R et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis 1999; 144(1):237-49.
81. German K, Kumar U, Blackford H. Garlic and the risk of TURP bleeding. British Journal of Urology 76, 518. 1995.
82. Piscitelli S, Burstein A, Welden N, Gallicano K, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clinical Infectious Diseases 34, 234-238. 2002.
83. Anthony MS, Clarkson TB, Williams JK. Effects of soy isoflavones on atherosclerosis: potential mechanisms. American Journal of Clinical Nutrition 68(6 Suppl):1390S-1393S, 1998.
84. Anderson J, Johnstone B, Cook-Newell M. Meta-analysis of the Effects of Soy Protein Intake on Serum Lipids. N Engl J Med 1995; 333:276-82.
85. Sacks FM, Lichtenstein A, Van HL et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113(7):1034-44, 2006.
86. Clerici C, Setchell KD, Battezzati P et al. Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. Journal of Nutrition 137[10], 2270-2278. 2007.
87. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. Journal of Clinical Endocrinology & Metabolism 86(7):3053-60, 2001.
88. Nestel PJ, Yamashita T, Sasahara T et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 17, 3392-3398. 1997.
89. Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. American Journal of Cardiology 85, 1297-1301. 2000.
90. Wiseman H, O’Reilly JD, Adlercreutz H et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. American Journal of Clinical Nutrition 72(2):395-400, 2000.
91. Jenkins DJ, Kendall CW, Jackson CJ et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. American Journal of Clinical Nutrition 76(2):365-72, 2002.
92. Thompson L, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. Nutrition and Cancer 16, 43-52. 1991.
93. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolarisciresinol diglucoside isolated form flaxseed. Circulation 99, 1355-1362. 1999.
94. Meagher L, Beecher G. Assessment of Data on the Lignan Content of Foods. Journal of Food Composition and Analysis 13, 935-947. 2000.
95. Hutchins A, Martini M, Olson B, Thomas W, Slavin J. Flaxseed influences urinary lignan excretion in a dose-dependent manner in postmenopausal women. Cancer Epidemiology, Biomarkers and Prevention 9[10], 1113-1118. 2000.
96. Sies H. Oxidative stress: oxidants and antioxidants. Experimental Physiology 82, 291-295. 1997.
97. Cox C, Wood KA. Selective antagonism of platelet activating factor (PAF)-induced aggregation and secretion of washed rabbit platelets by CV-2988, L-652731, triazolam and alprazolam. Thrombosis Research 47, 249. 1987.
98. Vanharanta M, Voutilainen S, Lakka TA, van der LM, Adlercreutz H, Salonen JT. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study.[see comment]. Lancet 354(9196):2112-5, 1999;-25.
99. Vanharanta M, Voutilainen S, Nurmi T et al. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis 160(2):465-9, 2002.
100. Kilkkinen A, Erlund I, Virtanen MJ, Alfthan G, Ariniemi K, Virtamo J. Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers. American Journal of Epidemiology 163(8):687-93, 2006.
101. Sanghvi A, Divven W, Seltman H. Inhihbition of rat liver cholesterol 7-alpha hydroxylase and acetyl CoA: cholesterol aceyl transferase activites by entrodiol and enterolactone. Proceedings of the Symposium on Drugs Affecting Lipid Metabolism , 311-322. 1984. New York, Plenum Press.
102. Kuroda T, Kondo K, Iwasaki T, Ohtani A, Takashima K. Synthesis and hypolipidemic activity of diesters of arylnapthalene lignan and their heteroarmoatic analogs. Chemical and Pharmaceutical Bulletin 162, 678-684. 1997.
103. Drexler H. Endothelial dysfunction. Prog Cardiovasc Dis 39, 287-324. 1997.
104. Chauhan A, More R, Mullins P, Taylor G, Petch C, Schofield PM. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. Journal of the American College of Cardiology 28, 1796-1804. 1996.
105. Yin WH, Chen J, Tsai C, Chiang MC, Young MS, Lin S. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clinical Nutrition 24, 988-997. 2005.
106. Blum A, Hathaway L, Mincemoyer R et al. Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy post-menopausal women. Journal of the American College of Cardiology 35, 271-276. 2000.
107. Schulman SP, Becker LC, Kass DA et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.[see comment]. JAMA 295(1):58-64, 2006.
108. Iyer RN, Khan AA, Gupta A, Vajifdar BU, Lokhandwala YY. L-carnitine moderately improves the exercise tolerance in chronic stable angina. Journal of the Association of Physicians of India 48(11):1050-2, 2000.
109. Cherchi A, Lai C, Onnis E et al. Propionyl carnitine in stable effort angina. Cardiovascular Drugs & Therapy 4(2):481-6, 1990.
110. Iliceto S, Scrutinio D, Bruzzi P et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. Journal of the American College of Cardiology 26(2):380-7, 1995.
111. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 106(4):215-23, 2006.
112. Atkins R. Dr. Atkins New Diet Revolution. 1997. Avon Books.
113. Heller R, Heller R. The Carbohydrate Addict’s Lifespan Program: A Personalized Plan for Becoming Slim, Fit and Healthy in Your 40s, 50s, 60s, and beyond. 1998. New York, NY, Penguin Books.
114. Craig J. Jenny Craig’s What Have you Got to Lose: A personalized Weight Management Program. 1992. New York, NY, Villard Books.
115. Simopoulos AP, Robinson J. The Omega Diet: The Lifesaving Nutritional Program Based on the Island of Crete. 1998. New York, NY, Harper Collins.
116. Ornish D. Dr. Dean Ornish’s Program for Reversing Heart Disease: The Only System Scientifically Proven to REverse Heart Disease Without Drugs or Surgery. 1996. Ivy Books.
117. Pritikin R. The New Pritikin Program: The Easy and Delicious Way to Shed Fat, Lower Your Cholesterol, and Stay Fit. 1991. New York, NY, Pocket Books.
118. Eades M. Protein Power: The High-Protein/Low Carbohydrate Way to Loose WEight, Feel Fit, and Boost Your Health-In Just Weeks. 21996. New York, NY, Bantam Books.
119. Schwarzbein D, Deville N. The Schwarzbein Principle. 1999. Health Communications.
120. Steward H, Bethea M, AndrewsS, Bennan R, Balart L. Sugar Busters! Cut Sugar to Trim Fat. 1998. New York, NY, Ballantine Books.
121. Somers S. Suzanne Somers’ Get Skinny on Fabulous Food. 1999. New York, NY, Crown.
122. Weight Watchers International Inc.Staff. Weight Watchers New Complete Cookbook. 1998. New York, NY, John Wiley & Sons.
123. Weil A. Eating Well for Optiumum Health: The Essential Guide to Food, Diet and Nutrition. 2000. New York, NY, Alfred Knopf.
124. Sears B, LawrenB. The Zone: A Dietary Road Map to Lose Weight Permanently: Reset Your Genetic Code: Prevent Disease: Achieve Maximum Physical Performance. 1995. New York, NY, Harper Collins.
125. Gould KL, Ornish D, Scherwitz L et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification [see comments]. Jama 1995; 274(11):894-901.
126. Ornish D, Scherwitz LW, Billings JH et al. Intensive lifestyle changes for reversal of coronary heart disease [published erratum appears in JAMA 1999 Apr 21;281(15):1380] [see comments]. Jama 1998; 280(23):2001-2007.
127. Koertge J, Weidner G, Elliott-Eller M et al. Improvement in Medical Risk Factors and Quality of Life in Women and Men with Coronary Artery Disease in the Multicenter Lifestyle Demonstration Project. American Journal of Cardiology 91, 1316-1322. 2003.
128. Lichtenstein AH, Van Horn L. Very low fat diets. Circulation 1998; 98(9):935-939.
129. Daubenmier J, Weidner G, Sumner M et al. The Contribution of Changes in Diet, Exercise, and Stress Management to Changes in Coronary Risk in Women and Men in the Multisite Cardiac Lifestyle Intervention Program. Annals of Behavioral Medicine 33[1], 57-68. 2007.
130. Keys A. Coronary heart disease in seven countries. Circulation 41(Suppl I), I-1-I-211. 1970.
131. Menotti A, Keys A, Kromhout D et al. Twenty-five year mortality from coronary heart disease and its prediction in five cohorts of middle-aged men in Finland, The Netherlands, and Italy. Preventive Medicine 19, 270-278. 1990.
132. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353, 1547-1557. 1999.
133. Kris-Etherton P, Eckel RH, Howard BV, St JS, Bazzarre TL, Nutrition Committee Population Science Committee and Clinical Science Committee of the American Heart Association. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease.[see comment]. Circulation 103(13):1823-5, 2001.
134. de Lorgeril M, Renaud S, Mamelle N et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343(8911):1454-1459.
135. Singh RB, Dubnov G, Niaz MA et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial.[see comment]. Lancet 360(9344):1455-61, 2002.
136. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99(6):779-785.
137. Trichopoulou A, Vasilopoulou E. Mediterranean diet and coronary heart disease; are antioxidants critical? Nutr Rev 2000; 57(8):253-255.
138. Estruch R, Martinez-Gonzalez MA, Corella D et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial.[summary for patients in Ann Intern Med. 2006 Jul 4;145(1):I11; PMID: 16818920]. Annals of Internal Medicine 145(1):1-11, 2006.
139. Michalsen A, Lehmann N, Pithan C et al. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease. European Journal of Clinical Nutrition 60(4):478-85, 2006.
140. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. Journal of the American College of Cardiology 44(1):152-8, 2004.
141. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 108(2):155-60, 2003.
142. Gronbaek M. Factors influencing the relation between alcohol and cardiovascular disease. Current Opinion in Lipidology 171, 17-21. 2006.
143. Szmitko P, Verman S. Antiatherogenic potential of red wine: clinicain update. American Journal of Physiology, Heart, and Circulatory Physiology 228, H2023-H2030. 2005.
144. Freedman M, King J, Kennedy E. Popular diets: a scientific review. Obesity Research 9 Suppl, 1S-40S. 2001.
145. St.Jeor S, Howard BV, Prewitt T, Bovee V, Bazzarre TL, Eckel RH. Dietary Protein and Weight Reduction: A Statement for Healthcare Professionals From the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 104[15], 1869-1874. 2001.
146. Fleming R, Boyd L. The effect of high-protein diets on coronary blood flow. Angiology 51, 817-826. 2005.
147. Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women.[see comment]. Journal of Clinical Endocrinology & Metabolism 88(4):1617-23, 2003.
148. Foster GD, Wyatt HR, Hill JO et al. A randomized trial of a low-carbohydrate diet for obesity.[see comment]. New England Journal of Medicine 348(21):2082-90, 2003.
149. Samaha FF, Iqbal N, Seshadri P et al. A low-carbohydrate as compared with a low-fat diet in severe obesity.[see comment]. New England Journal of Medicine 348(21):2074-81, 2003.
150. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severly obese adults: one-year follow-up of a randomized trial. Annals of Internal Medicine 140, 778-785. 2004.
151. Yancy WS, Jr., Olsen M, Guyton JR, Bakst R, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Annals of Internal Medicine 140, 769-777. 2004.
152. Dansinger M, Gleason J, Griffith J, Selker H, Schaefer E. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. Jama 293, 43-53. 2005.
153. Gardner CD, Kiazand A, Alhassan S et al. Comparison of the Atkins, Zone, Ornish, and LEARN Diets for Change in Weight and Related Risk Factors Among Overweight Premenopausal Women. The A to Z Weight Loss STudy: A Randomized Trial. Jama 297, 969-977. 2007.
154. Nordmann A, Nordmann A, Briel M et al. Effects of Low-Carbohydrate vs Low-Fat Diets on Weight loss and Cardiovascular Risk Factors. Archives of Internal Medicine 166, 285-293. 2006.
155. Knudtson ML, Wyse DG, Galbraith PD et al. Chelation therapy for ischemic heart disease: a randomized controlled trial.[see comment]. JAMA 287(4):481-6, 2002;-30.
156. Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J 2000; 140(1):4-5.
157. Anderson TJ, Hubacek J, Wyse DG, Knudtson ML. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. Journal of the American College of Cardiology 41(3):420-5, 2003.
158. Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovascular Disorders 5:32, 2005.
159. Lewin MR. Chelation therapy for cardiovascular disease. Review and commentary. [Review] [66 refs]. Texas Heart Institute Journal 24(2):81-9, 1997.
160. Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review.[see comment]. [Review] [36 refs]. Circulation 96(3):1031-3, 1997.
161. Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations [see comments]. [Review] [37 refs]. Am Heart J 2000; 140(1):139-141.
162. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. [Review] [17 refs]. Cochrane Database of Systematic Reviews (4):CD002785, 2002.
163. Chappell LT, Stahl J. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. Journal of Advancement in Medicine 6, 139-160. 1993.
164. Chappell L, Stahl J, Evans R. EDTA chelation treatment for vascular disease: a meta-analysis using unpublished data. Journal of Advancement in Medicine 1994; 7(3):131-142.
165. Sloth-Nielsen J, Guldager B, Mouritzen C et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. American Journal of Surgery 162, 122-125. 1991.
166. Morgan BW, Kori S, Thomas JD. Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic. Veterinary & Human Toxicology 44(5):274-6, 2002.
167. Wirebaugh S, Geraets D. Apparent failure of edetic acid chelation therapy for the treatment of coronary artherosclerosis. DICP 24, 22-25. 1990.
168. Guldager B, Jorgensen PJ, Grandjean P. Metal excretion and magnesium retention in patients with intermittent claudication treated with intravenous disodium EDTA. Clinical Chemistry 42, 1938-1942. 1996.
169. Kubzansky L, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? Journal of Psychosomatic Research 48, 323-337. 2000.
170. Ketterer M, Fitzgerald F, Thayer B et al. Psychosocial and traditional risk factors in early ischaemic heart disease: cross-sectional correlates. Journal of Cardiovascular Risk 7, 409-413. 2000.
171. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Archives of Internal Medicine 156, 745-752. 1996.
172. Dusseldorp E, van Elderen T, Maes S, Meulman J, Kraaij V. A meta-analysis of psychoeducational programs for coronary heart disease patients. Health Psychology 18, 506-519. 1999.
173. Paul-Labrador M, Polk D, Dwyer JH et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Archives of Internal Medicine 166(11):1218-24, 2006.
174. Schneider RH, Staggers F, Alxander CN et al. A randomised controlled trial of stress reduction for hypertension in older African Americans. Hypertension 26(5):820-7, 1995.
175. Castillo-Richmond A, Schneider RH, Alexander CN et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke 31(3):568-73, 2000.
176. Fields JZ, Walton KG, Schneider RH et al. Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of Maharishi Vedic Medicine. American Journal of Cardiology 89(8):952-8, 2002.
177. Canter PH, Ernst E. Insufficient evidence to conclude whether or not Transcendental Meditation decreases blood pressure: results of a systematic review of randomized clinical trials.[see comment]. [Review] [38 refs]. Journal of Hypertension 22(11):2049-54, 2004.
178. Innes KE, Bourguignon C, Taylor AG. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review. [Review] [172 refs]. Journal of the American Board of Family Practice 18(6):491-519, 2005;-Dec.
179. Lee MS, Lee MS, Kim HJ, Choi ES. Effects of qigong on blood pressure, high-density lipoprotein cholesterol and other lipid levels in essential hypertension patients. International Journal of Neuroscience 114(7):777-86, 2004.
180. Hui PN, Wan M, Chan WK, Yung PM. An evaluation of two behavioral rehabilitation programs, qigong versus progressive relaxation, in improving the quality of life in cardiac patients.[see comment]. Journal of Alternative & Complementary Medicine 12(4):373-8, 2006.
181. Mayer M. Qigong and hypertension: a critique of research. [Review] [90 refs]. Journal of Alternative & Complementary Medicine 5(4):371-82, 1999.
182. Tsai JC, Wang WH, Chan P et al. The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. Journal of Alternative & Complementary Medicine 9(5):747-54, 2003.
183. Thomas GN, Hong AW, Tomlinson B et al. Effects of Tai Chi and resistance training on cardiovascular risk factors in elderly Chinese subjects: a 12-month longitudinal, randomized, controlled intervention study. Clinical Endocrinology 63(6):663-9, 2005.
184. Motivala SJ, Sollers J, Thayer J, Irwin MR. Tai Chi Chih acutely decreases sympathetic nervous system activity in older adults. Journals of Gerontology Series A-Biological Sciences & Medical Sciences 61(11):1177-80, 2006.
| The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. |